Skip to main content

Analysis of the serological response to Chlamydia pneumoniae in patients with ischemic heart disease by recombinant MOMP-ELISA

Abstract.

To investigate the humoral immune response to the major outer membrane protein (MOMP) of Chlamydia pneumoniae, a fusion protein, thioredoxin-(His)6-MOMP (rMOMP) was produced in Escherichia coli and purified; this served as an antigen to establish an enzyme-linked immunosorbent assay (ELISA). Specific IgG and IgA antibodies against rMOMP were determined in sera from patients with ischemic heart disease. The findings were compared with those obtained by ELISA using the outer membrane protein complex (Hitazyme). The positivity rates for IgG antibody by rMOMP-ELISA were low (28%) compared with those by Hitazyme (72%). However, the positivity rates of IgA antibody by rMOMP-ELISA were similar to those by Hitazyme (76%). Interestingly, antigen positivity by immunohistochemical staining in the atherosclerotic lesions of coronary arteries was high in the groups with a high IgA titer of rMOMP-ELISA.

This is a preview of subscription content, access via your institution.

Author information

Authors and Affiliations

Authors

Additional information

Received: March 8, 2001 / Accepted: June 13, 2001

About this article

Cite this article

Kido, Y., Shirai, M., Ouchi, K. et al. Analysis of the serological response to Chlamydia pneumoniae in patients with ischemic heart disease by recombinant MOMP-ELISA. J Infect Chemother 7, 180–185 (2001). https://doi.org/10.1007/s101560100032

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s101560100032

  • Key wordsChlamydia pneumoniae
  • Recombinant MOMP
  • ELISA
  • Coronary heart disease